Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Enterprise Value (2016 - 2025)

Neurocrine Biosciences' Enterprise Value history spans 16 years, with the latest figure at -$1.5 billion for Q4 2025.

  • For Q4 2025, Enterprise Value fell 37.57% year-over-year to -$1.5 billion; the TTM value through Dec 2025 reached -$1.5 billion, down 37.57%, while the annual FY2025 figure was -$1.5 billion, 37.57% down from the prior year.
  • Enterprise Value reached -$1.5 billion in Q4 2025 per NBIX's latest filing, down from -$1.1 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$648.3 million in Q2 2022 to a low of -$1.5 billion in Q4 2025.
  • Average Enterprise Value over 5 years is -$971.1 million, with a median of -$976.2 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: grew 26.74% in 2022, then plummeted 50.66% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$714.5 million in 2021, then plummeted by 39.55% to -$997.1 million in 2022, then fell by 4.26% to -$1.0 billion in 2023, then fell by 3.51% to -$1.1 billion in 2024, then plummeted by 37.57% to -$1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Enterprise Value are -$1.5 billion (Q4 2025), -$1.1 billion (Q3 2025), and -$975.6 million (Q2 2025).